Published in Circulation on September 08, 2014
Stroke and anticoagulation in heart failure without atrial fibrillation: from risk to opportunity. Circulation (2015) 0.79
Patient-centered outcomes composites: a glimpse of the future. Circulation (2014) 0.77
Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. J Natl Cancer Inst (2016) 0.75
Global Outcome in Patients With Left Ventricular Assist Devices. Am J Cardiol (2017) 0.75
Getting (Along) With the Guidelines: Reconciling Patient Autonomy and Quality Improvement Through Shared Decision Making. Acad Med (2016) 0.75
Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research. Arq Bras Cardiol (2016) 0.75
Clinical Relevance of Rehospitalizations for Unstable Angina and Unplanned Revascularization Following Acute Myocardial Infarction. J Am Heart Assoc (2016) 0.75
Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet). Am Heart J (2015) 0.75
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med (2001) 6.38
Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA (2003) 5.67
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Trial and error. How to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol (2010) 2.45
Composite end points in randomized trials: there is no free lunch. JAMA (2010) 2.16
Univariate statistical analysis of environmental (compositional) data: problems and possibilities. Sci Total Environ (2009) 2.12
Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation (1990) 1.83
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J (2011) 1.58
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56
An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. Circulation (1992) 1.37
The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol (2008) 1.29
A method of assigning scores to the components of a composite outcome: an example from the MITI trial. Control Clin Trials (1992) 1.13
End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol (2009) 1.13
A global ranking approach to end points in trials of mechanical circulatory support devices. J Card Fail (2008) 1.05
Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol (2008) 1.05
The use of subjective rankings in clinical trials with an application to cardiovascular disease. Stat Med (1992) 1.01
Some old and some new statistical tools for outcomes research. Circulation (2008) 0.98
Clinical trials--multiple treatments, multiple end points, and multiple lessons. JAMA (2003) 0.92
Weighting composite endpoints in clinical trials: essential evidence for the heart team. Ann Thorac Surg (2012) 0.90
Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Stat Med (1997) 0.90
Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years. Stroke (2011) 0.89
Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction. Am J Cardiol (1997) 0.84